Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Fountoulakis, Konstantinos Ν.; Dragioti, Elena; Antonis, Theofilidis; Wikilund, Tobias; Atmatzidis, Xenofon; Nimatoudis, Ioannis; Thys, E; Wampers, Martien; Hranov, Luchezar; Hristova, Trayana; Aptalidis, Daniil; Milev, Roumen; Iftene, Felicia; Španiel, Filip; Knytl, Pavel; Fürstová, Petra; From, Tiina; Karlsson, H.; Walta, Maija; Salokangas, Raimo K. R.; Azorin, Jean‐Michel; Bouniard, Justine; Montant, J.; Juckel, Georg; Haußleiter, Ida Sybille; Douzenis, Athanasios; Michopoulos, Ioannis; Ferentinos, Panagiotis; Smyrnis, Nikolaos; Mantonakis, Leonidas; Nemes, Zsófia; Gonda, Xénia; Vajda, Dóra; Juhász, A.; Shrivastava, Amresh; Waddington, John L.; Pompili, Maurizio; Comparelli, Anna; Corigliano, Valentina; Rancāns, Elmārs; Navickas, Alvydas; Hilbig, Jan; Bukelskis, Laurynas; Stevović, Lidija Injac; Vodopić, Sanja; Esan, Oluyomi; Oladele, O. A.; Osunbote, Christopher; Rybakowski, Janusz; Wójciak, Paweł; Domowicz, Klaudia; Figueira, Maria Luísa; Linhares, Ludgero; Crawford, Joana; Panfil, Anca-Livia; Smirnova, Daria; Измайлова, О. В.; Lečić-Toševski, Dušica; Temmingh, Henk; Howells, Fleur M.; Bobes, Julio; García-Portilla, María Paz; García-Álvarez, Leticia; Erzın, Gamze; Karadağ, Hasan; Sousa, Avinash De; Bendre, Anuja; Höschl, Cyril; Bredicean, Cristina; Papavă, I.; Vuković, Olivera; Pejušković, Bojana; Russell, Vincent; Athanasiadis, Loukas; Konsta, Anastasia; Stein, Dan J.; Berk, Michael; Dean, Olivia; Tandon, Rajiv; Kasper, Siegfried; Hert, Marc De

doi:10.1093/ijnp/pyz053

Cited by 35 publications

(57 citation statements)

References 136 publications

(187 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides describing the most influential symptom domain of each stage, they also provided a timeline of the disorder. According to this timeline, stage 1 lasts about 3 years on average [25]. In this first stage, excitement and hostility symptoms were found to increase over time and becoming the leading symptom group of stage 2, that lasts Clinical Staging in Schizophrenia Spectrum Disorders DOI: http://dx.doi.org/10.5772/intechopen.98276 about 9 years on average [25].…”

Section: The Fountoulakis Staging Conceptmentioning

confidence: 90%

“…A novel concept of clinical staging in schizophrenia was proposed by Fountoulakis and colleagues in 2019 using the Positive and Negative Syndrome Scale (PANSS) and the 5-factor model (a model based on the notion that schizophrenia is characterized by positive, negative, cognitive, affective and hostility symptoms) [25]. They aimed to develop a staging concept empirically through analyzing a very large sample (n = 2358) of stabilized schizophrenia patients with varying ages [25]. Based on the results, they identified 4 major stages of schizophrenia (Figure 8), starting with stage 1, dominated by positive symptoms.…”

Section: The Fountoulakis Staging Conceptmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Staging in Schizophrenia Spectrum Disorders

Dombi¹,

Born²,

Sebe³

et al. 2022

Psychosis - Phenomenology, Psychopathology and Pathophysiology

View full text Add to dashboard Cite

The aim of this chapter is to summarize the state-of-the-art knowledge of clinical staging in schizophrenia spectrum disorders. Clinical staging has been introduced to psychiatry in the past two decades. Its primary goal is to divide the course of the disorder into recognizable stages based on seriousness, development and symptom characteristics in order to better predict prognosis and to adopt the most appropriate treatment strategies. The first staging model was developed in 1982. Since then several distinct concepts of clinical staging in psychiatry have emerged. To date, there is no clinical consensus regarding which staging model is the gold standard, nonetheless when merging them together an integrated staging concept arises. The integrated staging model of schizophrenia spectrum disorders is composed of four stages. The chapter will introduce the different staging models in a historical order as well as present the integrated staging model detailing the characteristics, timeline and dominating symptoms of each stage. Appropriate treatment strategies for the distinct stages will also be outlined.

show abstract

Section: The Fountoulakis Staging Conceptmentioning

confidence: 90%

Section: The Fountoulakis Staging Conceptmentioning

confidence: 99%

Clinical Staging in Schizophrenia Spectrum Disorders

Dombi¹,

Born²,

Sebe³

et al. 2022

Psychosis - Phenomenology, Psychopathology and Pathophysiology

View full text Add to dashboard Cite

show abstract

“…The factor scores for the subscales identified in our previous paper (positive [Po], negative [Ne], excitation/hostility [EH], depression and anxiety [DA], and neurocognitive impairment [Ncog]) have been used. 7…”

Section: Measurementsmentioning

confidence: 99%

“…The conclusion was that between centers, heterogeneity though present, had no impact on the results of that or the current study. 7…”

Section: Strengths and Limitations Of The Current Studymentioning

confidence: 99%

See 1 more Smart Citation

Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background. The aim of the current study was to explore the changing interrelationships among clinical variables through the stages of schizophrenia in order to assemble a comprehensive and meaningful disease model. Methods. Twenty-nine centers from 25 countries participated and included 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Multiple linear regression analysis and visual inspection of plots were performed. Results. The results suggest that with progression stages, there are changing correlations among Positive and Negative Syndrome Scale factors at each stage and each factor correlates with all the others in that particular stage, in which this factor is dominant. This internal structure further supports the validity of an already proposed four stages model, with positive symptoms dominating the first stage, excitement/hostility the second, depression the third, and neurocognitive decline the last stage. Conclusions. The current study investigated the mental organization and functioning in patients with schizophrenia in relation to different stages of illness progression. It revealed two distinct “cores” of schizophrenia, the “Positive” and the “Negative,” while neurocognitive decline escalates during the later stages. Future research should focus on the therapeutic implications of such a model. Stopping the progress of the illness could demand to stop the succession of stages. This could be achieved not only by both halting the triggering effect of positive and negative symptoms, but also by stopping the sensitization effect on the neural pathways responsible for the development of hostility, excitement, anxiety, and depression as well as the deleterious effect on neural networks responsible for neurocognition.

show abstract

Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial

Mohammadi,

Sadighi,

Nazeri Astaneh

et al. 2024

Neuropsychopharm Rep

View full text Add to dashboard Cite

AimManipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients.MethodsIn the present study, 70 patients (aged 18–65) with schizophrenia were recruited. Participants were randomly allocated to the placebo (n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups. Severity of disease and cognitive function (primary outcomes) were evaluated by Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MoCA) tests, respectively. Moreover, lipid profile, body mass index (BMI), gastrointestinal (GI) problems, serum C‐reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated as secondary outcomes.ResultsA total of 69 patients completed the study. The MoCA score was increased by 1.96 units in the probiotic‐containing supplement group compared to the placebo (p = 0.004). Also, the percentage of subjects with MoCA score ≥ 26 rose significantly in the intervention group (p = 0.031). Moreover, TC (p = 0.011), FBS (p = 0.009), and CRP (p < 0.001) significantly decreased in the supplement group compared to the placebo. Although the probiotic supplement reduced PANSS score by 2.82 units, the difference between the study groups was not statistically significant (p = 0.247).ConclusionCo‐administration of probiotics and vitamin D has beneficial effects on the improvement of cognitive function in schizophrenic patients.

show abstract

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Cited by 35 publications

References 136 publications

Clinical Staging in Schizophrenia Spectrum Disorders

Clinical Staging in Schizophrenia Spectrum Disorders

Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study

Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial

Contact Info

Product

Resources

About